ArcticZymes Technologies (AZT) Handelsbanken's Small & Mid Cap Seminar 2024 Presentation summary

Company overview

• Norwegian biotech focused on high-growth segments like molecular diagnostics and cell & gene therapy.

• Global sales split between US (40%) and Europe (60%), serving over 300 B2B customers.

• Products include novel enzymes for biomanufacturing and diagnostics, with a strong reputation and NPS of 84.

• 53 employees, headquartered in Tromsø, Norway, with ISO13485 and GMP compliance.

• Financially robust: >90% margins, 119 MNOK sales (2023), positive cash flow, no debt, and 240 MNOK cash reserve.

Market segments and solutions

• Focus on biomanufacturing (cell & gene therapies) and molecular diagnostics, both with strong growth outlooks.

• Enzymes used in gene therapy production and diagnostic assay technologies.

• Biomanufacturing market CAGR projected at 20% (2023–2030); molecular diagnostics at 5.4% (2023–2027).

• End-users include pharma, CDMOs, hospitals, labs, and researchers.

Transformation and strategic priorities

• Organizational restructuring reduced headcount by 23% in Q1 2024 and closed Oslo site.

• Strategic focus on balancing R&D and commercial resources, increasing product and brand marketing.

• Short-term: become more market-driven; long-term: build advanced therapies biomanufacturing pipeline.

• Initiatives include GMP upgrades, relaunching molecular tools, and expanding commercial channels.